Indian Journal of Surgical Oncology

, Volume 9, Issue 4, pp 511–518 | Cite as

Outcome of Bowel Resection in Women with Advanced Ovarian Carcinoma

  • Ajit Sebastian
  • Anitha Thomas
  • Gigi Varghese
  • Bijesh Yadav
  • Rachel Chandy
  • Abraham PeedicayilEmail author
Original Article


To evaluate the mortality and morbidity related to bowel resection in women with advanced ovarian carcinoma. Retrospective case series of 47 women with stage III and IV carcinoma ovary who underwent bowel resection, over the period of 5 years from Jan 2011 to Dec 2015. The risk factors for perioperative morbidity and death were determined by regression analysis. The disease free and overall survival were determined by Kaplan-Meier plots. In this cohort, 64% (30/47) had primary debulking, 21% (10/47) had interval debulking, and 15% (7/47) had secondary debulking. The mean period of follow-up was 23 months (1 to 45 months). There were no anastomotic leaks. The commonest morbidities were relaparotomy (8.5%), surgical site infection (12%), and paralytic ileus (19%). The overall morbidity was 42.6% (20/47). The 30-day mortality was 4.2% (2/47). The recurrence rate was 51% (20/47). The overall mortality from ovarian cancer in this cohort was 40% (19/47) during the follow-up period. Stage and histology seemed to be important risk factors for morbidity. Low BMI and sub-optimal debulking were significant risk factors for recurrence and death in univariate analysis. Bowel resection, in optimally selected cases of advanced carcinoma ovary, is often required for optimal cytoreduction. It carries a reasonable peri-operative mortality and morbidity and improves overall survival.


Ovarian cancer Bowel resection 


  1. 1.
    Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT et al (2003) Carcinoma of the ovary. Int J Gynecol Obstet 83(Suppl 1):135–166CrossRefGoogle Scholar
  2. 2.
    Pecorelli S, Favalli G, Zigliani L, Odicino F (2003) Cancer in women. Int J Gynecol Obstet 82:369–379CrossRefGoogle Scholar
  3. 3.
    Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21:3194–3200CrossRefGoogle Scholar
  4. 4.
    Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236CrossRefGoogle Scholar
  5. 5.
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43CrossRefGoogle Scholar
  6. 6.
    Bristow RE, Montz FJ (2001) Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 83:39–48CrossRefGoogle Scholar
  7. 7.
    Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizessurvival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69:103–108CrossRefGoogle Scholar
  8. 8.
    Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90:390–396CrossRefGoogle Scholar
  9. 9.
    Le T, Krepart GV, Lotocki RJ, Heywood MS (1997) Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 67:208–214CrossRefGoogle Scholar
  10. 10.
    Makar AP, Baekelandt M, Trope CG, Kristensen GB (1995) The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175–180CrossRefGoogle Scholar
  11. 11.
    Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE (2007) Survivalimpact of multiple bowel resections in patients undergoing primarycytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 107:495–499CrossRefGoogle Scholar
  12. 12.
    Estes JM, Leath CA 3rd, Straughn JM Jr, Rocconi RP, Kirby TO, Huh WK et al (2006) Bowel resection at the time of primary debulking for epithelial ovariancarcinoma: outcomes in patients treated with platinum and taxane-basedchemotherapy. J Am Coll Surg 203:527–532CrossRefGoogle Scholar
  13. 13.
    Bidzinski M, Derlatka P, Kubik P, Ziolkowska-Seta I, Dańska-Bidzinska A, Gmyrek L et al (2007) The evaluation of intra- and postoperative complicationsrelated to debulking surgery with bowel resection in patients with FIGOstage III-IV ovarian cancer. Int J Gynecol Cancer 17:993–997CrossRefGoogle Scholar
  14. 14.
    Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMedGoogle Scholar
  15. 15.
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259CrossRefGoogle Scholar
  16. 16.
    Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A (2007) Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian Cancer study group (AGO-OVAR). Gynecol Oncol 106:69–74CrossRefGoogle Scholar
  17. 17.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108:276–281CrossRefGoogle Scholar
  18. 18.
    Eisenkop SM, Spirtos NM, Lin WC (2006) “Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 103:329–335CrossRefGoogle Scholar
  19. 19.
    Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559–564CrossRefGoogle Scholar
  20. 20.
    Bristow RE, Del Carmen MG, Kaufman HS, Montz FJ (2003) Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 197:565–574CrossRefGoogle Scholar
  21. 21.
    Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC, Ward BG, Crandon AJ (2001) Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 83:115–120CrossRefGoogle Scholar
  22. 22.
    Chia YN, Tay EH, Cheong DM, Eu KW, Low J, Ho TH et al (2003) Bowel surgery for epithelial ovarian cancer—an early case series. Ann Acad Med Singap 32:661–664PubMedGoogle Scholar
  23. 23.
    Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A (2012) Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol 126:220–223CrossRefGoogle Scholar
  24. 24.
    Peeters KC, Tollenaar RA, Marijnen CA, Klein Kranenbarg E, Steup WH, Wiggers T et al (2005) Risk factors for anastomotic failure after total mesorectal excision of rectal cancer. Br J Surg 92:211–216CrossRefGoogle Scholar
  25. 25.
    Yeh CY, Changchien CR, Wang JY, Chen JS, Chen HH, Chiang JM, Tang R (2005) Pelvic drainage and other risk factors for leakage after elective anterior resection in rectal cancer patients: a prospective study of 978 patients. Ann Surg 241:9–13PubMedPubMedCentralGoogle Scholar
  26. 26.
    McArdle CS, McMillan DC, Hole DJ (2005) Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg 92:1150–1154CrossRefGoogle Scholar
  27. 27.
    Wong NY, Eu KW (2005) A defunctioning ileostomy does not prevent clinical anastomotic leak after a low anterior resection: a prospective, comparative study. Dis Colon Rectum 48:2076–2079CrossRefGoogle Scholar
  28. 28.
    Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH et al (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99:608–614CrossRefGoogle Scholar
  29. 29.
    Kalogera E, Dowdy SC, Mariani A, Weaver AL, Aletti G, Bakkum-Gamez JN, Cliby WA (2013) Multiple large bowel resections: potential risk factor for anastomotic leak. Gynecol Oncol 130:213–218CrossRefGoogle Scholar
  30. 30.
    Seah DW, Ibrahim S, Tay KH (2005) Hartmann procedure: is it still relevant today? ANZ J Surg 75:436–440CrossRefGoogle Scholar
  31. 31.
    Kyriazi S, Kaye SB, DeSouza NM (2010) Imaging ovarian cancer and peritoneal metastases—current and emerging techniques. Nat Rev Clin Oncol 7:381–393CrossRefGoogle Scholar
  32. 32.
    Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P et al (2014) Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol 24:889–901CrossRefGoogle Scholar
  33. 33.
    Levy A, Medjhoul A, Caramella C, Zareski E, Berges O, Chargari C, Boulet B, Bidault F, Dromain C, Balleyguier C (2011) Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: a review. J Magn Reson Imaging 33:1020–1027CrossRefGoogle Scholar
  34. 34.
    Scarabelli C, Gallo A, Franceschi S, Campagnutta E, De G, Giorda G et al (2000) Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 8:389–397CrossRefGoogle Scholar
  35. 35.
    Takahashi O, Sato N, Miura Y, Ogawa M, Fujimoto T, Tanaka H, Sato H, Tanaka T (2005) Surgical indications for combined partial rectosigmoidectomy in ovarian cancer. J Obstet Gynaecol Res 31:556–561CrossRefGoogle Scholar
  36. 36.
    Arora M, Saha S, Puthillath A, Sehgal R, Dutt N, Metz J, Misra A, Perez M, Wiese D, Singh T (2005) Impact of radical bowel resection on survival in advanced epithelial ovarian cancer. J Clin Oncol 23:5166CrossRefGoogle Scholar
  37. 37.
    Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR et al (2011) The impact of disease distribution on survival in patients with stage 3 epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study. Gynecol Oncol 122:521–526CrossRefGoogle Scholar
  38. 38.
    Fagotti A, Gallotta V, Romano F, Fanfani F, Rossitto C, Naldini A et al (2010) Peritoneal carcinosi of ovarian origin. World J Gastrointest Oncol 15:102–108CrossRefGoogle Scholar
  39. 39.
    Shimokawa M, Kogawa T, Shimada T, Saito T, Kumagai H, Ohki M, Kaku T (2018) Overall survival and post-progression survival are potent end point in phase III trials of second/third line chemotherapy for advanced or recurrent epithelial ovarian cancer. J Cancer 9:872–879CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of Gynaecologic OncologyCMC HospitalVelloreIndia
  2. 2.Department of Colorectal SurgeryCMC HospitalVelloreIndia
  3. 3.Department of BiostatisticsCMC HospitalVelloreIndia

Personalised recommendations